Background: Brain tumors can be serious and life-threatening when they are treated effectively. Many therapeutic approaches, such as chemotherapy, radiotherapy, and surgery have been used to treat brain tumors. In this regard, selenium supplements have been reported effective.
Methods: Selenium Nanoparticles (SeNPs) were produced in two forms of synthetic and biogenic to evaluate their cytotoxicity on brain glioblastoma cell lines. A-172 cell line was cultured in DMEM medium. The cytotoxicity of the synthetic and biogenic SeNP was assessed by MTT assay.
Results: There was a significant difference between the group treated with biogenic and synthetic SeNP compared with non-treated cells after 24, 48, and 72 h. Both biogenic and synthetic SeNP increased Bax gene and decreased Bcl-2 gene expression.
Conclusion: It seems that biogenic SeNP was more lethal than its synthetic form. Therefore, it should be considered that the method of NP construction may be an important parameter for its bioactivity.
Van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resistance Updates. 2015; 19:1-12. [DOI:10.1016/j.drup.2015.02.002] [PMID]
Zeng H, Combs GF. Selenium as an anticancer nutrient: Roles in cell proliferation and tumor cell invasion. The Journal of Nutritional Biochemistry. 2008; 19(1):1-7. [DOI:10.1016/j.jnutbio.2007.02.005] [PMID]
Hoffmann PR, Berry MJ. The Influence of selenium on immune responses. Molecular Nutrition & Food Research. 2008; 52(11):1273-80. [DOI:10.1002/mnfr.200700330] [PMID] [PMCID]
Ren F, Chen X, Hesketh J, Gan F, Huang K. Selenium promotes t-cell response to TCR-stimulation and ConA, but not PHA in primary porcine splenocytes. PLoS One. 2012; 7(4):e35375. [DOI:10.1371/journal.pone.0035375] [PMID] [PMCID]
Fakharzadeh S, Kalanaky S, Hafizi M, Goya MM, Masoumi Z, Namaki S, et al. The new nano-complex, Hep-c, improves the immunogenicity of the hepatitis B vaccine. Vaccine. 2013; 31(22):2591-7. [DOI:10.1016/j.vaccine.2013.03.030] [PMID]
Yazdi MH, Mahdavi M, Varastehmoradi B, Faramarzi MA, Shahverdi AR. The immunostimulatory effect of biogenic selenium nanoparticles on the 4T1 breast cancer model: An in vivo study. Biological Trace Element Research. 2012; 149(1):22-8. [DOI:10.1007/s12011-012-9402-0] [PMID]
Zhang S-Y, Zhang J, Wang H-Y, Chen H-Y. Synthesis of selenium nanoparticles in the presence of polysaccharides. Materials Letters. 2004; 58(21):2590-4. [DOI:10.1016/j.matlet.2004.03.031]
Faghfuri E, Yazdi MH, Mahdavi M, Sepehrizadeh Z, Faramarzi MA, Mavandadnejad F, et al. Dose-response relationship study of selenium nanoparticles as an immunostimulatory agent in cancer-bearing mice. Archives of Medical Research. 2015; 46(1):31-7. [DOI:10.1016/j.arcmed.2015.01.002] [PMID]
Molanouri Shamsi M, Chekachak S, Soudi S, Quinn LS, Ranjbar K, Chenari J, et al. Combined effect of aerobic interval training and selenium nanoparticles on expression of IL-15 and IL-10/TNF-α ratio in skeletal muscle of 4T1 breast cancer mice with cachexia. Cytokine. 2017; 90:100-8. [DOI:10.1016/j.cyto.2016.11.005] [PMID]
Mahmoudvand H, Shakibaie M, Tavakoli R, Jahanbakhsh S, Sharifi I. In vitro study of lLeishmanicidal activity of biogenic selenium nanoparticles against Iranian isolate of sensitive and glucantime-resistant leishmania tropica. Iranian Journal of Parasitology. 2014; 9(4):452-60.
Yazdi MH, Mahdavi M, Kheradmand E, Shahverdi AR. The preventive oral supplementation of a selenium nanoparticle-enriched probiotic increases the immune response and lifespan of 4T1 breast cancer bearing mice. Arzneimittelforschung. 2012; 62(11):525-31. [DOI:10.1055/s-0032-1323700] [PMID]
Alam M, Kashyap T, Mishra P, Panda AK, Nagini S, Mishra R. Role and regulation of proapoptotic Bax in oral squamous cell carcinoma and drug resistance. Head & Neck. 2019; 41(1):185-97. [DOI:10.1002/hed.25471] [PMID]
Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N. Proinflammatory cytokines in heart failure: Double-edged swords. Heart Failure Reviews. 2010; 15(6):543-62. [DOI:10.1007/s10741-010-9168-4] [PMID]
Kalhori M, Irani S, Soleimani M, Arefian E, Kouhkan F. [Effect of miR-579 overexpression on the BAX and CDKN1A genes in the Glioblastoma cell line. Pathobiology Research (Persian)]. 2019; 22(1):27-34.
Ozawa T, Hu JL, Hu LJ, Kong EL, Bollen AW, Lamborn KR, et al. Functionality of hypoxia-induced BAX expression in a human glioblastoma xenograft model. Cancer Gene Therapy. 2005; 12(5):449-55. [DOI:10.1038/sj.cgt.7700814] [PMID]